BMB-101 is all set to hit the clinic in H1’22 Unlike most biotechs developing drugs from naturally occurring psychedelics, Bright Minds is creating novel compounds that retain the therapeutic benefits of psychedelics while minimising side effects like heart valve diseases & hallucinations. We can draw parallels to the discovery of the anti-inflammatory drug ‘Aspirin’ in the 1800s, despite the existence of the naturally occurring pain reliever found in willow bark and used for centuries. The only probable difference is that we have prevailing drugs to treat depression and other neuro ailments. But these are effective only against mild-moderate cases and lead to severe side effects in some instances.
Bright Minds is creating a much-advanced version of the decades-old medicines to treat even severe neurological diseases. All this with a lower trip time and negligible side effects of the naturally occurring psychedelics and the first generation SSRIs.
https://www.takestockresearch.com/blog/bright-minds-biosciences%E2%80%99-nasdaqdrug-nces-progress-clinical-trials